<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="8af30ca1-ed3b-4775-806f-4fcc983548c5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use OSMITROL safely and effectively.  See full prescribing information for OSMITROL.<br/>
      <br/>OSMITROL (mannitol injection), for intravenous use<br/>Initial U.S. Approval: 1964</title>
   <effectiveTime value="20241119"/>
   <setId root="0d914965-7001-45cb-ba51-d7c5964b05bc"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Company</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="059140764" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0353" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0355" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0357" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0353" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0355" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0357" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0353" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0355" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0357" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0353" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0355" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0357" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0353" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0355" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0357" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194684502" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0353" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0355" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0357" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="334a61a9-0d39-4c38-93cf-d6e1adbc7cda"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20241119"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-0353" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Osmitrol</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Mannitol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="10"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0353-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19640608"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA013684" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19640608"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-0355" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Osmitrol</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Mannitol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="15"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0355-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19640608"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA013684" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19640608"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-0357" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Osmitrol</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Mannitol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="20"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="250"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0357-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19640608"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0357-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19640608"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA013684" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19640608"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_178AA0C1-3EDE-4F6D-BA4F-01E79BF5F057">
               <id root="02c50870-4b63-4d99-b7b6-ef5916adf799"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20181115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <paragraph>Indications and Usage (removed, revised) (<linkHtml href="#ID_07F15F43-A9D8-41CC-86A8-A3A2AE63E024">1</linkHtml>)                        11/2018<br/>Contraindications (<linkHtml href="#ID_DE571AF1-3A8D-4AB2-A9D6-0658DEC5E632">4</linkHtml>)                                                              11/2018<br/>Warnings and Precautions (<linkHtml href="#ID_00886549-53a2-4a66-986f-8dd9105f19e1">5.1</linkHtml>, <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">5.2</linkHtml>, <linkHtml href="#ID_479dd980-fff2-4b98-b3fe-c12e22505246">5.3</linkHtml>, <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">5.4</linkHtml>, <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">5.5</linkHtml>, <linkHtml href="#ID_99ae216b-9f3c-421f-965e-6ff971e8fbf7">5.6</linkHtml>, <linkHtml href="#ID_25d5995f-86d8-4ce4-a45b-25793ad28faa">5.7</linkHtml>)    11/2018</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_07F15F43-A9D8-41CC-86A8-A3A2AE63E024">
               <id root="f9af3e50-cbb4-448d-9201-1b550db48b48"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">OSMITROL is indicated for: </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="xmChange">The reduction of intracranial pressure and treatment of cerebral edema;</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="xmChange">The reduction of elevated intraocular pressure.</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20181115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>OSMITROL is an osmotic diuretic, indicated for the reduction of:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>intracranial pressure and treatment of cerebral edema. (<linkHtml href="#ID_07F15F43-A9D8-41CC-86A8-A3A2AE63E024">1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>elevated intraocular pressure. (<linkHtml href="#ID_07F15F43-A9D8-41CC-86A8-A3A2AE63E024">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_6FC30155-E700-47B6-9BEE-42C5D22759FA">
               <id root="ea8ed50c-b460-4f75-8e58-4dcb6838b2d0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20181115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration Instructions (</content>
                           <linkHtml href="#ID_15244b3b-fef4-4170-b9ba-450d7be86546">2.1</linkHtml>
                           <content styleCode="underline">):</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For intravenous infusion preferably into a large central vein.</item>
                           <item>
                              <caption>•</caption>Prior to administration, evaluate renal, cardiac and pulmonary status, and correct fluid and electrolyte imbalances.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage (</content>
                           <linkHtml href="#ID_c90285fb-1f53-40d0-bdf7-e4c5270e380e">2.2</linkHtml>
                           <content styleCode="underline">)</content>:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>The dosage, concentration and rate of administration depend on the age, weight and condition of the patient, including fluid requirement, urinary output and concomitant therapy.</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Reduction of Intracranial Pressure</content>: 0.25 gram/kg administered every 6 to 8 hours as an intravenous infusion over 30 minutes.</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Reduction of Intraocular Pressure</content>: 1.5 to 2 grams/kg of a 15% or 20% w/v solution as a single dose administered intravenously over at least 30 minutes.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_15244b3b-fef4-4170-b9ba-450d7be86546">
                     <id root="46774910-4e9f-4ab9-9fa4-902fa1dfe9b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Preparation and Administration Instructions </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>OSMITROL is for intravenous infusion preferably into a large central vein <content styleCode="italics">[see <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">Warnings and Precautions (5.5)</linkHtml>, <linkHtml href="#ID_7B8B98DB-48AB-407C-8703-47648CD6582E">Description (11)</linkHtml>].</content>
                           </item>
                           <item>
                              <caption>•</caption>Prior to administration of OSMITROL, evaluate renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances <content styleCode="italics">[see <linkHtml href="#ID_c90285fb-1f53-40d0-bdf7-e4c5270e380e">Dosage and Administration (2.2)</linkHtml>].</content>
                           </item>
                           <item>
                              <caption>•</caption>Do not administer OSMITROL simultaneously with blood products through the same administration set because of the possibility of pseudoagglutination or hemolysis.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Preparation</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Tear overwrap down side at slit and remove solution container.</item>
                           <item>
                              <caption>2.</caption>Visually inspect the container. Do not administer unless solution is clear and seal is intact.<list listType="ordered">
                                 <item>
                                    <caption>o</caption>If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. </item>
                                 <item>
                                    <caption>o</caption>Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.</item>
                              </list>
                           </item>
                           <item>
                              <caption>3.</caption>Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.</item>
                           <item>
                              <caption>4.</caption>Admixing OSMITROL with other medications is not recommended.</item>
                           <item>
                              <caption>5.</caption>Inspect OSMITROL visually for particulate matter and discoloration prior to administration. If particulates or discoloration are present, discard the bag. </item>
                           <item>
                              <caption>6.</caption>OSMITROL solutions may crystallize when exposed to low temperature. At higher concentrations, the solutions have a greater tendency to crystallize. Inspect OSMITROL for crystals prior to administration. If crystals are visible, re-dissolve by warming the solution up to 70°C, with agitation. Solutions should not be heated in water or in a microwave oven due to potential for product contamination or damage. Allow the solution to cool to room or body temperature before re-inspection for crystals and use.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Suspend container from eyelet support.</item>
                           <item>
                              <caption>2.</caption>Remove protector from outlet port at bottom of container.</item>
                           <item>
                              <caption>3.</caption>Attach administration set. Refer to complete directions accompanying set.</item>
                           <item>
                              <caption>4.</caption>Use administration sets with a final in-line filter because of the potential for OSMITROL crystals to form.</item>
                           <item>
                              <caption>5.</caption>To prevent air embolism, use a non-vented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible containers in series, fully evacuate residual gas in the container prior to administration, do not pressurize the flexible container to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the container runs dry. </item>
                           <item>
                              <caption>6.</caption>For single use only; discard unused portion.</item>
                        </list>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c90285fb-1f53-40d0-bdf7-e4c5270e380e">
                     <id root="f14f6cee-bdc3-4dc7-9c77-e94ca64e5309"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage </title>
                     <text>
                        <paragraph>Prior to administration of OSMITROL, evaluate renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances.</paragraph>
                        <paragraph>The total dosage, concentration, and rate of administration depend on the age, weight, and condition of the patient being treated, including fluid requirement, electrolyte balance, serum osmolality, urinary output, and concomitant therapy.</paragraph>
                        <paragraph>The following outline of administration and dosage is only a general guide to therapy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Reduction of Intracranial Pressure<br/>
                           </content>Usually a maximum reduction in intracranial pressure can be achieved with a dose of 0.25 gram/kg given intravenously as an intravenous infusion over 30 minutes which may be repeated every six to eight hours.</paragraph>
                        <paragraph>During and following OSMITROL infusion, monitor fluid and electrolytes, serum osmolarity, and renal, cardiac and pulmonary function. Discontinue OSMITROL if renal, cardiac, or pulmonary status worsens or CNS toxicity develops <content styleCode="italics">[see <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#ID_479dd980-fff2-4b98-b3fe-c12e22505246">5.3</linkHtml>, <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">5.4</linkHtml>, <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">5.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Reduction of Intraocular Pressure</content>
                        </paragraph>
                        <paragraph>The recommended dosage is 1.5 to 2 grams/kg of a 20% w/v solution (7.5 to 10 mL/kg) or as a 15% w/v solution (10 to 13 mL/kg) as a single dose administered intravenously over at least 30 minutes. When used preoperatively, administer OSMITROL sixty to ninety minutes before surgery to achieve maximal reduction of intraocular pressure before operation.</paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_007EF13D-8A48-4A2E-87CA-FE7AA20EE2C0">
               <id root="92c092d9-7f4e-418f-8f57-d86acfd0fa31"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>OSMITROL Injection:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>10% (0.1 grams/mL): 10 grams of mannitol, USP per 100 mL in a single-dose 500 mL flexible container</item>
                     <item>
                        <caption>•</caption>15% (0.15 grams/mL): 15 grams of mannitol, USP per 100 mL in a single-dose 500 mL flexible container</item>
                     <item>
                        <caption>•</caption>20% (0.2 grams/mL): 20 grams of mannitol, USP per 100 mL in single-dose 250 mL and 500 mL flexible containers</item>
                  </list>
               </text>
               <effectiveTime value="20241119"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection (<linkHtml href="#ID_007EF13D-8A48-4A2E-87CA-FE7AA20EE2C0">3</linkHtml>):</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>10% (0.1 grams/mL): 10 grams of mannitol, USP per 100 mL in a single-dose 500 mL flexible container</item>
                           <item>
                              <caption>•</caption>15% (0.15 grams/mL): 15 grams of mannitol, USP per 100 mL in a single-dose 500 mL flexible container</item>
                           <item>
                              <caption>•</caption>20% (0.2 grams/mL): 20 grams of mannitol, USP per 100 mL in single-dose 250 mL and 500 mL flexible containers</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_DE571AF1-3A8D-4AB2-A9D6-0658DEC5E632">
               <id root="c90525aa-5360-4df9-9405-c7a5f6f1ed1f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">OSMITROL is contraindicated in patients with: </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="xmChange">Known hypersensitivity to mannitol [see <linkHtml href="#ID_00886549-53a2-4a66-986f-8dd9105f19e1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="xmChange">Anuria [see <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="xmChange">Severe hypovolemia [see <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="xmChange">Pre-existing severe pulmonary vascular congestion or pulmonary edema [see <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="xmChange">Active intracranial bleeding except during craniotomy</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20181115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Known hypersensitivity to mannitol. (<linkHtml href="#ID_DE571AF1-3A8D-4AB2-A9D6-0658DEC5E632">4</linkHtml>, <linkHtml href="#ID_00886549-53a2-4a66-986f-8dd9105f19e1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Anuria. (<linkHtml href="#ID_DE571AF1-3A8D-4AB2-A9D6-0658DEC5E632">4</linkHtml>, <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Severe hypovolemia. (<linkHtml href="#ID_DE571AF1-3A8D-4AB2-A9D6-0658DEC5E632">4</linkHtml>, <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Pre-existing severe pulmonary vascular congestion or pulmonary edema. (<linkHtml href="#ID_DE571AF1-3A8D-4AB2-A9D6-0658DEC5E632">4</linkHtml>, <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Active intracranial bleeding except during craniotomy. (<linkHtml href="#ID_DE571AF1-3A8D-4AB2-A9D6-0658DEC5E632">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_2D4364B4-B18A-4EA0-823D-D827954A1445">
               <id root="bbe0317a-f3e2-4417-abbe-a5bd6d12eca0"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20181115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hypersensitivity Reactions, including anaphylaxis</content>: Stop infusion immediately if hypersensitivity reactions develop. (<linkHtml href="#ID_00886549-53a2-4a66-986f-8dd9105f19e1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Renal Complications Including Renal Failure</content>: Risk factors include pre-existing renal failure, concomitant use of nephrotoxic drugs or other diuretics. Avoid use of nephrotoxic drugs. Discontinue OSMITROL if renal function worsens. (<linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">5.2</linkHtml>, <linkHtml href="#ID_2B1ABAEB-FC7A-48EC-B5F7-781362AABC0C">8.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Central Nervous System (CNS) Toxicity</content>: Confusion, lethargy and coma may occur during or after infusion. Concomitant neurotoxic drugs may potentiate toxicity. Avoid use of neurotoxic drugs. Discontinue OSMITROL if CNS toxicity develops. (<linkHtml href="#ID_479dd980-fff2-4b98-b3fe-c12e22505246">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Fluid and Electrolyte Imbalances, Hyperosmolarity</content>: Hypervolemia may exacerbate congestive heart failure, hyponatremia can lead to encephalopathy; hypo/hyperkalemia can result in cardiac adverse reactions in sensitive patients. Discontinue OSMITROL if fluid and/or electrolyte imbalances occur. (<linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Monitoring/Laboratory Tests</content>: Monitor fluid and electrolytes, serum osmolarity and renal, cardiac and pulmonary function. Discontinue if toxicity develops. (<linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Infusion Site Reactions</content>: May include irritation and inflammation, as well as severe reactions (compartment syndrome) when associated with extravasation. (<linkHtml href="#ID_99ae216b-9f3c-421f-965e-6ff971e8fbf7">5.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Interference with Laboratory Tests</content>: High concentrations of mannitol may cause false low results of inorganic phosphorus blood concentrations. Mannitol may produce false positive results for blood ethylene glycol. (<linkHtml href="#ID_25d5995f-86d8-4ce4-a45b-25793ad28faa">5.7</linkHtml>, <linkHtml href="#ID_65e4f8a4-646c-4388-bdff-1dfb1274a23e">7.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_00886549-53a2-4a66-986f-8dd9105f19e1">
                     <id root="b33d163f-b90d-48c2-a178-32220f0710ee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.1 Hypersensitivity Reactions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Serious hypersensitivity reactions, including anaphylaxis, hypotension and dyspnea resulting in cardiac arrest and death have been reported with OSMITROL [see <linkHtml href="#ID_552FC09A-593F-4A0E-BDF4-59340B82FCD7">Adverse Reactions (6)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Stop the infusion immediately if signs or symptoms of a suspected hypersensitivity reaction develop. Initiate appropriate therapeutic countermeasures as clinically indicated.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">
                     <id root="9334da42-d2fb-4240-bf2e-6bca8d042f4a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.2 Renal Complications Including Renal Failure</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Renal complications, including irreversible renal failure have been reported in patients receiving mannitol. Reversible, oliguric acute kidney injury (AKI) has occurred in patients with normal pretreatment renal function who received large intravenous doses of mannitol. Although the osmotic nephrosis associated with mannitol administration is in principle reversible, osmotic nephrosis in general is known to potentially proceed chronic or even end-stage renal failure. Monitor renal function closely, including signs of urine output reduction, during OSMITROL infusion. Patients with pre-existing renal disease, patients with conditions that put them at high risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure following administration of OSMITROL. Avoid concomitant administration of nephrotoxic drugs (e.g., aminoglycosides) or, other diuretics with OSMITROL, if possible [see <linkHtml href="#ID_a3df3f36-25e6-482b-b8c1-b701c5168327">Drug Interactions (7.1</linkHtml>, <linkHtml href="#ID_e3c5d0f2-73aa-4739-b696-92ce07078bc0">7.2</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Patients with oliguric AKI who subsequently develop anuria while receiving mannitol are at risk of congestive heart failure, pulmonary edema, hypertensive crisis, coma and death.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">During and following OSMITROL infusion for the reduction in intracranial pressure, monitor the patient clinically and laboratory tests for changes in fluid and electrolyte status. Discontinue OSMITROL if renal function worsens. [see <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_479dd980-fff2-4b98-b3fe-c12e22505246">
                     <id root="2037a818-c04b-4815-b735-6548c6390fce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.3 Central Nervous System (CNS) Toxicity</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">CNS toxicity manifested by, e.g., confusion, lethargy, coma has been reported in patients treated with mannitol, some resulting in death, in particular in the presence of impaired renal function CNS toxicity may result from high serum mannitol concentrations, serum hyperosmolarity resulting in intracellular dehydration within CNS, hyponatremia or other disturbances of electrolyte and acid/base balance secondary to mannitol administration [see <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">At high concentrations, mannitol may cross the blood brain barrier and interfere with the ability of the brain to maintain the pH of the cerebrospinal fluid especially in the presence of acidosis.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In patients with preexisting compromise of the blood brain barrier, the risk of increasing cerebral edema (general and focal) associated with repeated or continued use of OSMITROL must be individually weighed against the expected benefits.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">A rebound increase of intracranial pressure may occur several hours after the infusion. Patients with a compromised blood brain barrier are at increased risk.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Concomitant administration of neurotoxic drugs (e.g., aminoglycosides) with OSMITROL may potentiate neurotoxicity. Avoid concomitant use of neurotoxic drugs, if possible [see <linkHtml href="#ID_2ac252e8-fbcc-4be9-855b-13f0d457260d">Drug Interactions (7.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">During and following OSMITROL infusion for the reduction in intracranial pressure, monitor the patient clinically and laboratory tests for changes in fluid and electrolyte status. Discontinue OSMITROL if CNS toxicity develops [see <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">
                     <id root="39b37dcf-51ad-41b7-92e5-c2c7947a9d71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.4 Fluid and Electrolyte Imbalances, Hyperosmolarity</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Depending on dosage and duration, administration of OSMITROL may result in hypervolemia leading to or exacerbating existing congestive heart failure. Accumulation of mannitol due to insufficient renal excretion increases the risk of hypervolemia. Mannitol-induced osmotic diuresis may cause or worsen dehydration/hypovolemia and hemoconcentration. Administration of OSMITROL may also cause hyperosmolarity [see <linkHtml href="#ID_7B8B98DB-48AB-407C-8703-47648CD6582E">Description (11)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Depending on dosage and duration of administration, electrolyte and acid/base imbalances may also result from <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">transcellular shifts in water and electrolytes, osmotic diuresis and/or other mechanisms. Such imbalances may be severe</linkHtml> and potentially fatal.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Imbalances that may result from OSMITROL administration include:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">Hypernatremia, dehydration and hemoconcentration</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">Hyponatremia, which can lead to headache, nausea, seizures, lethargy, coma, cerebral edema, and death. Acute symptomatic hyponatremic encephalopathy is considered a medical emergency.</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">Hypo/hyperkalemia. The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, agents that may cause QT prolongation, neuromuscular blocking agents) [see <linkHtml href="#ID_e3e159e3-e445-411e-a358-3ab44b1c5f77">Drug Interactions (7.4)</linkHtml>].</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">Other electrolyte disturbances</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">Metabolic acidosis/alkalosis</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange">Pediatric patients less than two years of age, particularly preterm and term neonates, may be at higher risk for fluid and electrolyte abnormalities following OSMITROL administration due to decreased glomerular filtration rate and limited ability to concentrate urine [see <linkHtml href="#ID_7850c3c6-7ddf-4d5c-b184-de4cfe5745a4">Use in Specific Populations (8.4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">During and following OSMITROL infusion for the reduction in intracranial pressure, monitor fluid and electrolyte status and discontinue OSMITROL if imbalances occur [see <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">
                     <id root="d8e62ee9-c7f7-48f7-873c-77784a3573b9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.5 Monitoring/Laboratory Tests</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">During and following OSMITROL infusion for the reduction in intracranial pressure, monitor:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">serum osmolarity, serum electrolytes (including sodium, potassium, calcium and phosphate) and acid base balance,</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">the osmol gap</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">signs of hypo- or hypervolemia, including urine output</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">renal, cardiac and pulmonary function</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">intracranial pressure</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange">Discontinue OSMITROL if renal, cardiac, or pulmonary status worsens or CNS toxicity develops [see <linkHtml href="#ID_DE571AF1-3A8D-4AB2-A9D6-0658DEC5E632">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_99ae216b-9f3c-421f-965e-6ff971e8fbf7">
                     <id root="731c3cbd-8a4d-4d77-8585-10e094373bf5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.6 Infusion Site Reactions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">The infusion of hypertonic solutions through a peripheral vein, including OSMITROL at a concentration of 10% w/v or greater, may result in peripheral venous irritation, including phlebitis. Other severe infusion site reactions, such as compartment syndrome and swelling associated with extravasation, can occur with administration of OSMITROL [see <linkHtml href="#ID_552FC09A-593F-4A0E-BDF4-59340B82FCD7">Adverse Reactions (6)</linkHtml>]. OSMITROL is preferably for administration into a large central vein [see <linkHtml href="#ID_15244b3b-fef4-4170-b9ba-450d7be86546">Dosage and Administration (2.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_25d5995f-86d8-4ce4-a45b-25793ad28faa">
                     <id root="b6352cf8-74f2-482c-86b8-a4943892107e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.7 Interference with Laboratory Tests</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">High concentrations of mannitol can cause false low results for inorganic phosphorus blood concentrations [see <linkHtml href="#ID_65e4f8a4-646c-4388-bdff-1dfb1274a23e">Drug Interactions (7.6)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Mannitol may produce false positive results in tests for blood ethylene glycol concentrations [see <linkHtml href="#ID_65e4f8a4-646c-4388-bdff-1dfb1274a23e">Drug Interactions (7.6)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_552FC09A-593F-4A0E-BDF4-59340B82FCD7">
               <id root="bf7e7a3b-ed9d-4f09-8da5-cc3f6c5f144c"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following adverse reactions from voluntary reports or clinical studies have been reported with OSMITROL. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Hypersensitivity reactions</content>: cardiac arrest, anaphylaxis, hypotension, dyspnea, hypertension, pyrexia, chills, sweating, cough, musculoskeletal stiffness, myalgia, urticarial/rash, pruritus, generalized pain, discomfort, nausea, vomiting, and headache. <content styleCode="italics">[see <linkHtml href="#ID_00886549-53a2-4a66-986f-8dd9105f19e1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Renal Failure</content>: acute kidney injury, osmotic nephrosis, azotemia, anuria, hematuria, oliguria, polyuria<content styleCode="italics"> [see <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">CNS Toxicity</content>: coma, seizures, confusion, lethargy; rebound increase in intracranial pressure; dizziness<content styleCode="italics"> [see <linkHtml href="#ID_479dd980-fff2-4b98-b3fe-c12e22505246">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Fluid and Electrolyte Imbalances</content>: hypovolemia, hypervolemia, peripheral edema, dehydration, hyponatremia, hypernatremia, hyperkalemia, hypokalemia; metabolic acidosis<content styleCode="italics"> [see <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Infusion Site Reactions</content>: phlebitis, inflammation, pain, rash, erythema, pruritus; compartment syndrome and swelling associated with extravasation <content styleCode="italics">[see <linkHtml href="#ID_99ae216b-9f3c-421f-965e-6ff971e8fbf7">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Cardiac and Respiratory Disorders</content>: congestive cardiac failure, pulmonary edema, palpitations</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Gastrointestinal Disorders</content>: thirst, dry mouth</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">General Disorders</content>: asthenia, malaise</item>
                  </list>
               </text>
               <effectiveTime value="20181115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption> </caption>The most common adverse reactions are hypersensitivity reactions, renal failure, CNS toxicity, hypo/hypervolemia, hypo/hypernatremia, hypo/hyperkalemia, and infusion site reactions. (<linkHtml href="#ID_552FC09A-593F-4A0E-BDF4-59340B82FCD7">6</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Baxter Healthcare at 1-866-888-2472</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_1E1ECE5A-CE99-489F-8E61-2708BFF93430">
               <id root="a729950a-b7ee-412c-845e-9e3ba95075b0"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20181115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Nephrotoxic Drugs and Diuretics</content>: May increase the risk of renal failure; avoid concomitant use. (<linkHtml href="#ID_a3df3f36-25e6-482b-b8c1-b701c5168327">7.1</linkHtml>, <linkHtml href="#ID_e3c5d0f2-73aa-4739-b696-92ce07078bc0">7.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Neurotoxic Drugs</content>: May potentiate CNS toxicity of mannitol; avoid concomitant use. (<linkHtml href="#ID_2ac252e8-fbcc-4be9-855b-13f0d457260d">7.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Drugs Affected by Electrolyte Imbalances</content>: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue OSMITROL if cardiac status worsens. (<linkHtml href="#ID_e3e159e3-e445-411e-a358-3ab44b1c5f77">7.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Renally Eliminated Agents</content>: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (<linkHtml href="#ID_255151ed-8511-4376-80b5-b645bdeccbf4">7.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_a3df3f36-25e6-482b-b8c1-b701c5168327">
                     <id root="6b8b9ff7-9793-4b42-bb92-1f41d56ea44f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Nephrotoxic Drugs </title>
                     <text>
                        <paragraph>Concomitant administration of nephrotoxic drugs (e.g., cyclosporine, aminoglycosides) increases the risk of renal failure following administration of mannitol. Avoid use of nephrotoxic drugs with OSMITROL, if possible <content styleCode="italics">[see <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e3c5d0f2-73aa-4739-b696-92ce07078bc0">
                     <id root="475d5be4-09a8-4619-a8ce-d25ba47d8768"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Diuretics </title>
                     <text>
                        <paragraph>Concomitant administration of other diuretics may potentiate the renal toxicity of mannitol. Avoid use of other diuretics with OSMITROL, if possible <content styleCode="italics">[see <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2ac252e8-fbcc-4be9-855b-13f0d457260d">
                     <id root="4c1518e8-099e-4fa6-ae09-8d10b1ce1d65"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Neurotoxic Drugs </title>
                     <text>
                        <paragraph>Concomitant administration of systemic neurotoxic drugs (e.g., aminoglycosides) with OSMITROL may potentiate the CNS toxicity of mannitol. Avoid use of systemic neurotoxic drugs with OSMITROL, if possible<content styleCode="italics"> [see <linkHtml href="#ID_479dd980-fff2-4b98-b3fe-c12e22505246">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e3e159e3-e445-411e-a358-3ab44b1c5f77">
                     <id root="f49c70d7-6c16-4956-95f8-ecf661c1567f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Drugs Affected by Electrolyte Imbalances </title>
                     <text>
                        <paragraph>The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, drugs that prolong the QT interval, neuromuscular blocking agents) <content styleCode="italics">[see <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">Warnings and Precautions (5.4)</linkHtml>].</content> During and following OSMITROL infusion, monitor serum electrolytes and discontinue OSMITROL if cardiac status worsens <content styleCode="italics">[see <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_255151ed-8511-4376-80b5-b645bdeccbf4">
                     <id root="d58ba9a7-ecb8-49b0-9378-91ba872fdbc9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Renally Eliminated Drugs </title>
                     <text>
                        <paragraph>Mannitol therapy may increase the elimination, and decrease the effectiveness of treatment with, drugs that undergo significant renal elimination. Concomitant administration of mannitol with lithium may initially increase the elimination of lithium but may also increase the risk of lithium toxicity if patients develop hypovolemia or renal impairment. In patients receiving lithium, consider holding lithium doses during treatment with OSMITROL. In patients requiring concomitant administration of lithium and OSMITROL, frequently monitor serum lithium concentrations and for signs of lithium toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_65e4f8a4-646c-4388-bdff-1dfb1274a23e">
                     <id root="19317ece-1836-4af9-ab15-56fdc734a799"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 Interference with Laboratory Tests </title>
                     <text>
                        <paragraph>High concentrations of mannitol can cause false low results for inorganic phosphorus blood concentrations when an assay based on the conversion of phosphate (orthophosphate) to the phosphomolybdate complex is used.</paragraph>
                        <paragraph>Mannitol may produce false positive results in tests for blood ethylene glycol concentrations in which mannitol is initially oxidized to an aldehyde.</paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4A06E3B5-5C1B-481F-8721-32BEBABA8278">
               <id root="96f33123-4bdc-448a-9fba-c1bde9e74b01"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20181115"/>
               <component>
                  <section ID="ID_B106EC9E-A067-4A85-A344-28198942FB57">
                     <id root="6aad3dad-fd5a-4a36-b051-df89c5866be7"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20181115"/>
                     <component>
                        <section ID="ID_f1d74b51-c5c4-4e21-81be-c378402d10f6">
                           <id root="2c78d4ce-169c-4329-990b-66979b46bad4"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>The available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus <content styleCode="italics">(see Data)</content>. No adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal infusion of mannitol. </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20181115"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_17b1f43b-aa11-4325-ab31-62fa26c23ff2">
                           <id root="85e50210-296d-4eb7-8729-b735bde46dfe"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Human Data</content>
                              </paragraph>
                              <paragraph>Published literature reports the presence of mannitol in amniotic fluid when mannitol is administered to pregnant women during the third trimester of pregnancy.</paragraph>
                           </text>
                           <effectiveTime value="20181115"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_2B1ABAEB-FC7A-48EC-B5F7-781362AABC0C">
                     <id root="94790081-7261-4ec8-8dd7-098235f4e31b"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of mannitol in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for OSMITROL and any potential adverse effects on the breastfed infant from OSMITROL or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7850c3c6-7ddf-4d5c-b184-de4cfe5745a4">
                     <id root="812517d1-d683-4704-acbc-0496bdc6c534"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>OSMITROL is approved for use in the pediatric population for the reduction of intracranial and intraocular pressure. Studies have not defined the optimal dose of OSMITROL in the pediatric population. The safety profile for mannitol use in pediatric patients is similar to adults at dosages described in labeling. However, pediatric patients less than two years of age, particularly preterm and term neonates, may be at higher risk for fluid and electrolyte abnormalities following OSMITROL administration due to decreased glomerular filtration rate and limited ability to concentrate urine<content styleCode="italics"> [see <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">Warnings and Precautions (5.4</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f147cfbf-b95f-4e5d-ab95-150edee099e9">
                     <id root="4f41a31b-0387-46d4-93e6-b6bfecaae24a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Mannitol is known to be substantially excreted by the kidney and the risk of adverse reactions to this drug may be greater in elderly patients with impaired renal function. Evaluate the renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of OSMITROL <content styleCode="italics">[see <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#ID_479dd980-fff2-4b98-b3fe-c12e22505246">5.3</linkHtml>, <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">5.4</linkHtml>, <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">5.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_23c9bec4-69e8-44c6-b950-0f9db39ad563">
                     <id root="a2f84677-aaed-4c10-9736-53216ac13342"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment </title>
                     <text>
                        <paragraph>Patients with pre-existing renal disease, patients with conditions that put them at high risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure with administration of mannitol. Evaluate the renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of OSMITROL <content styleCode="italics">[see <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#ID_479dd980-fff2-4b98-b3fe-c12e22505246">5.3</linkHtml>, <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">5.4</linkHtml>, <linkHtml href="#ID_7745255a-b38f-4484-a9e0-6a34f18e8a14">5.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8A8CE05E-B168-4D77-88DF-D0635FB7EA44">
               <id root="16550344-2545-48c6-8645-9c9de720ff9b"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Signs and symptoms of overdose with OSMITROL include renal failure and AKI, hypo/hypervolemia, hyperosmolarity and electrolyte imbalances, CNS toxicity (e.g., coma, seizures), some of which can be fatal <content styleCode="italics">[see <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#ID_479dd980-fff2-4b98-b3fe-c12e22505246">5.3</linkHtml>, <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">5.4</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>Management of overdosage with OSMITROL is symptomatic and supportive. Discontinue the infusion and institute appropriate corrective measures with particular attention to renal, cardiac and pulmonary systems<content styleCode="italics">.</content> Correct fluid and electrolyte imbalances.</paragraph>
                  <paragraph>OSMITROL is dialyzable (hemodialysis and peritoneal dialysis), hemodialysis may increase OSMITROL elimination.</paragraph>
               </text>
               <effectiveTime value="20181115"/>
            </section>
         </component>
         <component>
            <section ID="ID_7B8B98DB-48AB-407C-8703-47648CD6582E">
               <id root="584f6be1-93ae-4c4c-b5ca-da0c7ba83d63"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>OSMITROL is a sterile, nonpyrogenic solution of Mannitol, USP in a single-dose flexible container for intravenous administration as an osmotic diuretic. It contains no antimicrobial agents. Mannitol is a six carbon sugar alcohol prepared commercially by the reduction of dextrose. The pH is adjusted with sodium hydroxide or hydrochloric acid. Composition, osmolarity, and pH are shown in <linkHtml href="#_Ref8116387">Table 1</linkHtml>.</paragraph>
                  <table width="100%">
                     <col width="19%"/>
                     <col width="16%"/>
                     <col width="25%"/>
                     <col width="25%"/>
                     <col width="15%"/>
                     <tbody>
                        <tr>
                           <td rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>Table 1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph> Size </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Composition</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <footnote ID="_RefID6AC81E2525024DAFA0577B365177486B">Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.</footnote>Osmolarity</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                              <paragraph>pH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph> (mL)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Mannitol, USP <br/>(g/L)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>(mOsmol/L) <br/>(calc)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule " valign="middle">
                              <paragraph>10% <br/>OSMITROL </paragraph>
                           </td>
                           <td align="center" styleCode="Lrule Botrule " valign="middle">
                              <paragraph>500</paragraph>
                           </td>
                           <td align="center" styleCode="Lrule Botrule " valign="middle">
                              <paragraph>100</paragraph>
                           </td>
                           <td align="center" styleCode="Lrule Botrule " valign="middle">
                              <paragraph>549</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>5.0 <br/>(4.5 TO 7.0)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule " valign="middle">
                              <paragraph>15% <br/>OSMITROL </paragraph>
                           </td>
                           <td align="center" styleCode="Lrule Botrule " valign="middle">
                              <paragraph>500</paragraph>
                           </td>
                           <td align="center" styleCode="Lrule Botrule " valign="middle">
                              <paragraph>150</paragraph>
                           </td>
                           <td align="center" styleCode="Lrule Botrule " valign="middle">
                              <paragraph>823</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>5.0 <br/>(4.5 TO 7.0)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="2" styleCode="Lrule Botrule " valign="middle">
                              <paragraph>20% <br/>OSMITROL </paragraph>
                           </td>
                           <td align="center" styleCode="Lrule Botrule " valign="middle">
                              <paragraph>250</paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode="Lrule Toprule Botrule " valign="middle">
                              <paragraph>200</paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode="Lrule Toprule Botrule " valign="middle">
                              <paragraph>1098</paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>5.0 <br/>(4.5 TO 7.0)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>500</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <renderMultiMedia ID="id574" referencedObject="B66734F0-9788-461F-B403-14EAD0BDE683"/>
                  <paragraph>The plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.</paragraph>
               </text>
               <effectiveTime value="20241119"/>
               <component>
                  <observationMedia ID="B66734F0-9788-461F-B403-14EAD0BDE683">
                     <text>Osmitrol Injection Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_EBDB12DA-E9EB-4AE8-A951-9F3E51A8C2B8">
               <id root="5d52c37c-3e96-40a6-b77c-080128a8ebfb"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20181115"/>
               <component>
                  <section ID="ID_34F600CD-0BDE-469C-8793-9A3CBCDF95E4">
                     <id root="061adc46-0410-41b3-9ffd-ca8b4034b28e"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Mannitol, when administered intravenously, exerts its osmotic diuretic effect as a solute of relatively small molecular size being largely confined to the extracellular space. Mannitol hinders tubular reabsorption of water and enhances excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate.</paragraph>
                        <paragraph>This increase in extracellular osmolarity affected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure, intracranial edema, and intraocular pressure.</paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_59C6D391-7AF9-4758-B217-A3CE4B93CC2B">
                     <id root="9a36eaf1-3431-4f7e-87cb-f7c9cb1e1365"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Mannitol distributes largely in the extracellular space in 20 to 40 minutes after intravenous administration. The volume of distribution of mannitol is approximately 17 L in adults.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>In subjects with normal renal function, the total clearance is 87 to 109 mL/min. The elimination half-life of mannitol is 0.5 to 2.5 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Only relatively small amount of the dose administered is metabolized after intravenous administration of mannitol to healthy subjects.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Mannitol is eliminated primarily via the kidneys in unchanged form. Mannitol is filtered by the glomeruli, exhibits less than 10% of tubular reabsorption, and is not secreted by tubular cells. Following intravenous administration, approximately 80% of an administered dose of mannitol is estimated to be excreted in the urine in three hours with lesser amounts thereafter.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>In patients with renal impairment, the elimination half-life of mannitol is prolonged. In a published study, in patients with renal impairment including acute renal failure and end stage renal failure, the elimination half-life of mannitol was estimated at about 36 hours, based on serum osmolarity. In patients with renal impairment on dialysis, the elimination half-life of mannitol was reduced to 6 and 21 hours during hemodialysis and peritoneal dialysis, respectively.<content styleCode="italics"> [see <linkHtml href="#ID_2B1ABAEB-FC7A-48EC-B5F7-781362AABC0C">Use in Specific Populations (8.6)</linkHtml>, <linkHtml href="#ID_8A8CE05E-B168-4D77-88DF-D0635FB7EA44">Overdosage (10)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_005B90EB-4133-4647-A9A1-F8881AEDB10F">
               <id root="414be206-1a48-496f-a3c4-f4ae84b22dd5"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>OSMITROL injection is supplied in single-dose, flexible VIAFLEX plastic containers and is available as follows: </paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <col width="19%"/>
                     <col width="20%"/>
                     <col width="25%"/>
                     <col width="35%"/>
                     <tbody>
                        <tr>
                           <td valign="top">
                              <paragraph>Code</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Size (mL)</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>NDC</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Product Name</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>2D5613</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>500</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>0338-0353-03</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>10% (0.1 g/mL mannitol, USP)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>2D5623</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>500</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>0338-0355-03</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>15% (0.15 g/mL mannitol, USP)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>2D5632</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>250</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>0338-0357-02</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>20% (0.2 g/mL mannitol, USP)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>2D5633</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>500</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>0338-0357-03</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>20% (0.2 g/mL mannitol, USP)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Do not remove container from overwrap until intended for use.</paragraph>
                  <paragraph>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Store at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.</paragraph>
               </text>
               <effectiveTime value="20241119"/>
            </section>
         </component>
         <component>
            <section ID="ID_8C64A2BA-290D-4265-84AF-F1AB5C9D2A8D">
               <id root="e67c727e-f031-4da3-a582-fb8cbba761de"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Inform patients or caregivers of the following risks of OSMITROL:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#ID_00886549-53a2-4a66-986f-8dd9105f19e1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Renal Failure <content styleCode="italics">[see <linkHtml href="#ID_ee9a38e7-ae16-457c-8dc3-e3ce1138076d">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>CNS Toxicity <content styleCode="italics">[see <linkHtml href="#ID_479dd980-fff2-4b98-b3fe-c12e22505246">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Fluid and Electrolyte Imbalances, Hyperosmolarity <content styleCode="italics">[see <linkHtml href="#ID_925b9aa1-eb06-4dd0-949a-3518ffc51acb">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Infusion Site Reactions <content styleCode="italics">[see <linkHtml href="#ID_99ae216b-9f3c-421f-965e-6ff971e8fbf7">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20181115"/>
            </section>
         </component>
         <component>
            <section ID="ID_28ca87c8-26e3-496c-ac70-73ac66a655ee">
               <id root="468dc1a3-0e16-4ce2-8a88-089e72aaa1ae"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:<br/>Baxter Healthcare Corporation<br/>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>Printed in USA</paragraph>
                  <paragraph>Baxter, Osmitrol, and Viaflex are trademarks of Baxter International Inc.</paragraph>
                  <paragraph>07-19-00-8824</paragraph>
                  <paragraph>Rev. Nov, 2024</paragraph>
               </text>
               <effectiveTime value="20241119"/>
            </section>
         </component>
         <component>
            <section ID="ID_89D8F0B1-BCB3-46FC-9660-78FD5D78FDD9">
               <id root="3c3b09d0-88f5-4105-a6bf-64f9c7c18119"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <content styleCode="bold">
                     <renderMultiMedia ID="id-1698077092" referencedObject="BA97C219-B4B5-4653-BA6B-CA85FBA7937A">
                        <caption>Container Label</caption>
                     </renderMultiMedia>
                  </content>
                  <paragraph>
                     <content styleCode="bold">2D5613</content>
                     <br/>
                     <content styleCode="bold">NDC 0338-0353-03</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10% OSMITROL</content>
                     <br/>
                     <content styleCode="bold">Injection</content>
                     <br/>
                     <content styleCode="bold">(10% Mannitol</content>
                     <br/>
                     <content styleCode="bold">Injection USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mL</content>
                  </paragraph>
                  <paragraph>EACH 100 mL CONTAINS 10 g MANNITOL USP pH <br/>ADJUSTED WITH SODIUM HYDROXIDE OR HYDROCHLORIC ACID <br/>pH 5.0 (4.5 TO 7.0) HYPERTONIC OSMOLARITY 549 <br/>mOsmol/L (CALC) STERILE NONPYROGENIC SINGLE DOSE <br/>CONTAINER OSMOTIC DIURETIC DOSAGE INTRAVENOUSLY<br/>AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS <br/>SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT <br/>STERILITY DISCARD IF LEAKS ARE FOUND DO NOT <br/>ADMINISTER SIMULTANEOUSLY WITH BLOOD MUST NOT BE <br/>USED IN SERIES CONNECTIONS DO NOT USE UNLESS<br/>SOLUTION IS CLEAR <content styleCode="bold">RX ONLY </content>STORE UNIT IN MOISTURE <br/>BARRIER OVERWRAP AT ROOM TEMPERATURE (25<content styleCode="bold">°</content>C/77<content styleCode="bold">º</content>F) <br/>UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT</paragraph>
                  <paragraph>VIAFLEX CONTAINER<br/>PL 146 PLASTIC</paragraph>
                  <paragraph>FOR PRODUCT INFORMATION<br/>1-800-933-0303</paragraph>
                  <paragraph>BAXTER OSMITROL VIAFLEX<br/>AND PL 146 ARE TRADEMARKS OF<br/>BAXTER INTERNATIONAL INC </paragraph>
                  <paragraph>
                     <content styleCode="bold">BAXTER HEALTHCARE CORPORATION</content>
                     <br/>DEERFIELD IL 60015 USA<br/>MADE IN USA</paragraph>
                  <content styleCode="bold">
                     <renderMultiMedia ID="id638765289" referencedObject="ID_51a6db39-6f6f-4365-9051-d62283569fb7">
                        <caption>Container Label</caption>
                     </renderMultiMedia>
                  </content>
                  <paragraph>
                     <content styleCode="bold">2D5623</content>
                     <br/>
                     <content styleCode="bold">NDC 0338-0355-03</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">15% OSMITROL</content>
                     <br/>
                     <content styleCode="bold">Injection</content>
                     <br/>
                     <content styleCode="bold">(15% Mannitol</content>
                     <br/>
                     <content styleCode="bold">Injection USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mL</content>
                  </paragraph>
                  <paragraph>EACH 100 mL CONTAINS 15 g MANNITOL USP pH ADJUSTED WITH <br/>SODIUM HYDROXIDE OR HYDROCHLORIC ACID  pH 5.0 (4.5 TO 7.0) <br/>OSMOLARITY 823 mOsmol/L (CALC) HYPERTONIC MAY CAUSE<br/>VEIN DAMAGE STERILE NONPYROGENIC SINGLE DOSE CONTAINER <br/>OSMOTIC DIURETIC DOSAGE INTRAVENOUSLY AS DIRECTED BY A <br/>PHYSICIAN USING A <content styleCode="bold">FILTER TYPE</content> SET SEE DIRECTIONS CAUTIONS <br/>SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITY <br/>DISCARD IF LEAKS ARE FOUND DO NOT ADMINISTER SIMULTANEOUSLY <br/>WITH BLOOD MUST NOT BE USED IN SERIES CONNECTIONS DO NOT <br/>USE UNLESS SOLUTION IS CLEAR  IF CRYSTALS ARE VISIBLE REDISSOLVE<br/>BY WARMING UNIT TO 70°C/158°F WITH AGITATION  COOL TO ROOM<br/>TEMPERATURE AND REINSPECT FOR CRYSTALS BEFORE INFUSION<content styleCode="bold">
                        <br/>RX ONLY </content>STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM <br/>TEMPERATURE (25<content styleCode="bold">°</content>C/77<content styleCode="bold">º</content>F) UNTIL READY TO USE AVOID EXCESSIVE <br/>HEAT SEE INSERT</paragraph>
                  <paragraph>VIAFLEX CONTAINER<br/>PL 146 PLASTIC</paragraph>
                  <paragraph>FOR PRODUCT INFORMATION<br/>1-800-933-0303</paragraph>
                  <paragraph>BAXTER OSMITROL VIAFLEX<br/>AND PL 146 ARE TRADEMARKS OF<br/>BAXTER INTERNATIONAL INC </paragraph>
                  <paragraph>
                     <content styleCode="bold">BAXTER HEALTHCARE CORPORATION</content>
                     <br/>DEERFIELD IL 60015 USA<br/>MADE IN USA</paragraph>
                  <content styleCode="bold">
                     <renderMultiMedia ID="id1733270105" referencedObject="ID_897d2772-4a00-4228-acbc-698af3f5678d">
                        <caption>Container Label</caption>
                     </renderMultiMedia>
                  </content>
                  <paragraph>
                     <content styleCode="bold">LOT  EXP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2D5632</content>
                     <br/>
                     <content styleCode="bold">NDC 0338-0357-02</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">20% OSMITROL Injection</content>
                     <br/>
                     <content styleCode="bold">(20% Mannitol Injection USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">250 mL </content>EACH 100 mL CONTAINS <br/>20 g MANNITOL USP <br/>pH ADJUSTED WITH SODIUM HYDROXIDE OR <br/>HYDROCHLORIC ACID  pH 5.0 (4.5 TO 7.0) <br/>OSMOLARITY 1098 mOsmol/L (CALC) <br/>HYPERTONIC MAY CAUSE VEIN DAMAGE <br/>STERILE NONPYROGENIC SINGLE DOSE <br/>CONTAINER OSMOTIC DIURETIC DOSAGE<br/>INTRAVENOUSLY AS DIRECTED BY A <br/>PHYSICIAN USING A <content styleCode="bold">FILTER TYPE</content> SET SEE <br/>DIRECTIONS CAUTIONS SQUEEZE AND <br/>INSPECT INNER BAG WHICH MAINTAINS <br/>PRODUCT STERILITY DISCARD IF LEAKS ARE <br/>FOUND DO NOT ADMINISTER <br/>SIMULTANEOUSLY WITH BLOOD MUST NOT BE <br/>USED IN SERIES CONNECTIONS DO NOT USE <br/>UNLESS SOLUTION IS CLEAR  IF <br/>CRYSTALS ARE VISIBLE REDISSOLVE BY <br/>WARMING UNIT TO 70°C/158°F WITH <br/>AGITATION  COOL TO ROOM TEMPERATURE <br/>AND REINSPECT FOR CRYSTALS BEFORE <br/>INFUSION<content styleCode="bold"> RX ONLY </content>STORE UNIT IN <br/>MOISTURE BARRIER OVERWRAP AT ROOM <br/>TEMPERATURE (25<content styleCode="bold">°</content>C/77<content styleCode="bold">º</content>F) UNTIL READY TO <br/>USE AVOID EXCESSIVE HEAT SEE INSERT</paragraph>
                  <paragraph>VIAFLEX CONTAINER PL 146 PLASTIC</paragraph>
                  <paragraph>FOR PRODUCT INFORMATION<br/>1-800-933-0303</paragraph>
                  <paragraph>BAXTER OSMITROL VIAFLEX<br/>AND PL 146 ARE TRADEMARKS OF<br/>BAXTER INTERNATIONAL INC </paragraph>
                  <paragraph>
                     <content styleCode="bold">BAXTER HEALTHCARE CORPORATION</content>
                     <br/>DEERFIELD IL 60015 USA<br/>MADE IN USA</paragraph>
               </text>
               <effectiveTime value="20241119"/>
               <component>
                  <observationMedia ID="BA97C219-B4B5-4653-BA6B-CA85FBA7937A">
                     <text>Osmitrol Injection Representative Container Label  NDC 0338-053-03</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_51a6db39-6f6f-4365-9051-d62283569fb7">
                     <text>Osmitrol Injection Representative Container Label  NDC 0338-0355-03</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_897d2772-4a00-4228-acbc-698af3f5678d">
                     <text>Osmitrol Injection Representative Container Label  NDC 0338-0357-02</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>